Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Sep 15, 2020; 12(9): 1065-1072
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1065
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1065
Figure 1 Treatment course.
mCRC: Metastasis colorectal cancer; ctDNA: Circulating tumor DNA; HER2: Human epidermal growth factor receptor 2; APC: Adenomatous polyposis coli; TP53: Tumor protein 53; Amp: Amplification; Mut: mutation; XELOX: Capecitabine and oxaliplatin; Bev: Bevacizumab; FOLFIRI: 5-fluorouracil, leucovorin, and irinotecan; PD: Progressive disease; SD: Stable disease; PR: Partial response; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
- Citation: Guan JL, Liu JH, Wang Q, Cong YW, Chen YX, Huang KF, Huang ML, Huang L. Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report. World J Gastrointest Oncol 2020; 12(9): 1065-1072
- URL: https://www.wjgnet.com/1948-5204/full/v12/i9/1065.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i9.1065